Literature DB >> 18927281

Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.

Ursula Vinatzer1, Michaela Gollinger, Leonhard Müllauer, Markus Raderer, Andreas Chott, Berthold Streubel.   

Abstract

PURPOSE: The well-known translocations identified in MALT lymphomas include t(11;18)/API2-MALT1, t(1;14)/IGH-BCL10, and t(14;18)/IGH-MALT1. Molecular investigations have suggested that these three disparate translocations affect a common pathway, resulting in the constitutive activation of nuclear factor-kappaB. However, the vast majority of MALT lymphomas are negative for any of the above-mentioned translocations and the underlying pathogenesis is unclear. EXPERIMENTAL
DESIGN: Fresh tissue of 29 gastric and extragastric MALT lymphomas was studied for genetic aberrations by conventional karyotyping, long-distance inverse PCR (LDI-PCR), fluorescence in situ hybridization (FISH), reverse transcription-PCR (RT-PCR), and real-time quantitative RT-PCR (QRT-PCR).
RESULTS: Conventional cytogenetics, FISH, and RT-PCR identified aberrations in 26 of 29 MALT lymphoma. Balanced translocations were found in 21 cases. IGH was rearranged in the majority of cases with balanced translocations (n = 17/21); 3 cases had t(11;18)/API2-MALT1 and 1 case had novel t(6;7)(q25;q11), respectively. IGH partner genes involved MALT1, FOXP1, BCL6, and four new chromosomal regions on chromosome arms 1p, 1q, 5q, and 9p. LDI-PCR identified three novel partner genes on 1p (CNN3), 5q (ODZ2), and 9p (JMJD2C). FISH assays were established and confirmed LDI-PCR results. QRT-PCR showed deregulation of the novel genes in the translocation-positive cases.
CONCLUSIONS: Our study expands the knowledge on the genetic heterogeneity of MALT lymphomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927281     DOI: 10.1158/1078-0432.CCR-08-0702

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  Molecular mechanisms and potential functions of histone demethylases.

Authors:  Susanne Marije Kooistra; Kristian Helin
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

2.  Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.

Authors:  Roselyne M Labbé; Andreana Holowatyj; Zeng-Quan Yang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

3.  Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.

Authors:  Ling-Ling Sun; Andreana Holowatyj; Xiu-E Xu; Jian-Yi Wu; Zhi-Yong Wu; Jin-Hui Shen; Shao-Hong Wang; En-Min Li; Zeng-Quan Yang; Li-Yan Xu
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

4.  Epigenetic dysregulation in cancer.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 5.  From MALT lymphoma to the CBM signalosome: three decades of discovery.

Authors:  Shaun Rosebeck; Aasia O Rehman; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

6.  Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.

Authors:  Tae-Dong Kim; James R Fuchs; Eric Schwartz; Dalia Abdelhamid; Jonathan Etter; William L Berry; Chenglong Li; Michael A Ihnat; Pui-Kai Li; Ralf Janknecht
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

Review 7.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

Review 9.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

10.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.